MaaT Pharma Strengthens Executive Team Appointing Jonathan Chriqui as Chief Business Officer
March 21 2024 - 12:00PM
Business Wire
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage
biotechnology company and a leader in the development of Microbiome
Ecosystem TherapiesTM (MET) dedicated to enhancing survival for
patients with cancer, today announced the appointment of Jonathan
Chriqui, PharmD, as Chief Business Officer and member of the
executive management team. Jonathan Chriqui will be responsible for
MaaT Pharma’s business development and partnering strategies along
with promoting MaaT Pharma's innovations within the microbiome
industry.
“We are very pleased to welcome Jonathan at this pivotal time
for MaaT Pharma. Jonathan’s expertise and extensive experience will
be instrumental in securing strategic partnerships and maximizing
the potential of our pipeline. MaaT Pharma is now poised to propel
its lead asset, MaaT013, into the next phase of development and
prepare for its commercial launch,” said Hervé Affagard, Chief
Executive Officer and co-founder of MaaT Pharma.
Jonathan brings over 15 years of business development experience
working at Ipsen and Servier, including leadership in strategic
transactions in the field of microbiota as well as collaborations,
licensing, M&A, and alliance management. Previously, he held
the role of Chief Operating & Chief Business Development
Officer at Somagenetix in Zurich, Switzerland, which is developing
gene therapies for rare diseases in immunology, neurology, and
oncology.
“The gut microbiome as a therapeutic modality holds the
potential to transform cancer treatment, and I'm thrilled to join
MaaT Pharma. My goal is to support the growth of the company, which
is recognized worldwide for its technology leadership and
innovative approach towards oncology indications. I look forward to
contributing to the advancement of MaaT013 towards the market and
supporting the company’s mission of providing new treatment options
for patients with cancer,” shared Jonathan Chriqui, Chief
Business Officer at MaaT Pharma.
About MaaT Pharma
MaaT Pharma, a clinical-stage biotechnology company, has
established a complete approach to restoring patient-microbiome
symbiosis in oncology. Committed to treating cancer and
graft-versus-host disease (GvHD), a serious complication of
allogeneic stem cell transplantation, MaaT Pharma has launched, in
March 2022, an open-label, single-arm Phase 3 clinical trial in
patients with acute GvHD, following the achievement of its proof of
concept in a Phase 2 trial. Its powerful discovery and analysis
platform, gutPrint®, enables the identification of novel disease
targets, evaluation of drug candidates, and identification of
biomarkers for microbiome-related conditions. The company’s
Microbiome Ecosystem Therapies are produced through a standardized
cGMP manufacturing and quality control process to safely deliver
the full diversity of the microbiome in liquid and oral
formulations. MaaT Pharma benefits from the commitment of
world-leading scientists and established relationships with
regulators to support the integration of the use of microbiome
therapies in clinical practice. MaaT Pharma is listed on Euronext
Paris (ticker: MAAT).
Forward-looking Statements
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240321071270/en/
MaaT Pharma – Investor Relations Guilhaume DEBROAS, Ph.D.
Head of Investor Relations +33 6 16 48 92 50
invest@maat-pharma.com
MaaT Pharma – Media Relations Pauline RICHAUD Senior PR
& Corporate Communications Manager +33 6 14 06 45 92
media@maat-pharma.com
Trophic Communications – Corporate Communications Jacob
VERGHESE or Priscillia PERRIN +49 151 7441 6179 maat@trophic.eu
Maat Pharma (EU:MAAT)
Historical Stock Chart
From May 2024 to Jun 2024
Maat Pharma (EU:MAAT)
Historical Stock Chart
From Jun 2023 to Jun 2024